Key facts
- It has raised $2.2M; the latest was Early Stage VC ($2.2M) in Jun 2025.
- Notable investors include Coalition for Epidemic Preparedness Innovations, The University of Texas Medical Branch.
- Status: Privately Held (backing).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Emervax
- ·The full record, as it builds
Funding rounds
No funding rounds for Emervax are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Emervax
Developer of an mRNA-based vaccine platform designed for viral infectious diseases, including those that have the highest potential to cause epidemics and pandemics. The company's platform specializes in discovering next-generation vaccines for the prevention and control of emerging viruses and chronic diseases, enabling users to address global health challenges.
- Sector
- Healthcare
- HQ
- Houston, TX, United States
- Founded
- 2022
- Employees
- 5
- Website
- emervax.com/
- Ownership
- Privately Held (backing)
Emervax doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Emervax shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Emervax in its N-PORT filings yet. We sweep new filings monthly.